Neurogene (NGNE) shares were down about 13% in recent trading Friday after Baird downgraded the company to neutral from outperform and lowered the price target to $24 from $38.
Trading volume stood at nearly 144,000 shares against a daily average of about 270,000 shares.
Price: 16.91, Change: -2.47, Percent Change: -12.73